2022
   Ljubljana, Slovenia

I-01 João Abrantes ADaMO: End-to-end automation of Pharmacometric modelling in drug development, from dataset building to output generation Wednesday 09:45-11:15

I-02 Nicolas Azzopardi Mechanistic model of contrast-enhanced ultrasound in colorectal cancer metastasis. Wednesday 09:45-11:15

I-03 Freya Bachmann Computing Optimal Drug Dosing with OptiDose: Implementation in NONMEM Wednesday 09:45-11:15

I-04 Aliénor Bergès Model informed drug development to accelerate clinical development in life cycle innovation Wednesday 09:45-11:15

I-05 Monir Bertayli Dose determination of morphine to investigate the analgesic effects of morphine and pregabalin in healthy subjects using a combined NONMEM model Wednesday 09:45-11:15

I-06 Mattia Berton Repository of model parameters for physiologically based pharmacokinetic modelling in obese validated against triazolam and caffeine observed data Wednesday 09:45-11:15

I-07 Jantine Brussee Population PK modelling for the iminosugar lucerastat supports dose adaptation in patients with Fabry disease and moderate to severe renal impairment Wednesday 09:45-11:15

I-08 Laura Bukkems Relationship between factor VIII activity levels and bleeding for rFVIII-SingleChain in patients with severe hemophilia A Wednesday 09:45-11:15

I-09 Myriam Chartoire Investigation of the design of the capsaicin cough challenge test Wednesday 09:45-11:15

I-10 Chao Chen The area under the effect curve as a preclinical-to-clinical translation tool for predicting therapeutic dose of anti-infectives Wednesday 09:45-11:15

I-11 Henrik Cordes Species-specific Expression Databases for Physiologically Based Pharmacokinetic Modeling Wednesday 09:45-11:15

I-12 Vincent Croixmarie Dose selection and adaptation strategy in renal impaired patients for a phase 2 study with a Clinical Trial Simulation strategy Wednesday 09:45-11:15

I-13 Anna Dari Quantifying the Persistence of Immunogenicity After a Single Dose of Ad26.COV2.S in Humans Using a Mechanistic Modeling & Simulation Approach Wednesday 09:45-11:15

I-14 Alessandro Di Deo Evaluation of the pharmacokinetics of tideglusib in congenital and childhood myotonic dystrophy type 1 using Bayesian priors Wednesday 09:45-11:15

I-15 Alan Faraj Model-informed dose selection in phase-3 trials for prophylactic treatment with dalcinonacog alfa in adult and pediatric hemophilia B patients Wednesday 09:45-11:15

I-16 Alan Faraj A joint ketamine and esketamine exposure-response model of MADRS score in major depressive disorder to enable informed trial design for candidate drugs with similar mode of action Wednesday 09:45-11:15

I-17 Thomas Frank Population pharmacokinetic/pharmacodynamic modeling to demonstrate comparability of exposure and activity of insulin aspart Sanofi Wednesday 09:45-11:15

I-18 Aline Fuchs The human FcRn transgenic mice Tg32 as a model for early assessment and prediction of human pharmacokinetics of monoclonal antibodies Wednesday 09:45-11:15

I-19 Iztok Grabnar Pharmacokinetic-pharmacodynamic model of fentanyl sedation in children with severe acute bronchiolitis Wednesday 09:45-11:15

I-20 Mélanie Guhl Computation of standard errors at finite distance in non linear mixed effects models Wednesday 09:45-11:15

I-21 Benjamin Guiastrennec A Bounded Integer Approach to Evaluate AIMS Score for Austedo in Patients with Tardive Dyskinesia Wednesday 09:45-11:15

I-22 Seiichi Hayato Population pharmacokinetics and exposure-response analyses of amyloid PET SUVr and plasma biomarkers Aβ42/40 ratio and p-tau181 for lecanemab in subjects with early Alzheimer’s disease Wednesday 09:45-11:15

I-23 Chih-hsuan Hsin Hepatic impairment affects pharmacokinetics and pharmacodynamics of selatogrel, a novel subcutaneous P2Y12 receptor antagonist Wednesday 09:45-11:15

I-24 Laura Iavarone Application of the Area Under the Effect Curve as in vivo efficacy driver in Visceral Leishmaniasis Wednesday 09:45-11:15

I-25 Woojin Jung Containerized NONMEM and its assistant software in R development environment Wednesday 09:45-11:15

I-26 Angela Khodzhayev Esophageal Eosinophil Count and the Endoscopic Reference Score Remodeling Subscore Do Not Correlate in Placebo Treated Eosinophilic Esophagitis Patients: Phase 2 Proof-of-Concept and Phase 3 TREET Studies Wednesday 09:45-11:15

I-27 Jane Knöchel Accelerating clinical development of a novel PCSK9 antisense oligonucleotide using semi-mechanistic pharmacodynamic modelling Wednesday 09:45-11:15

I-28 Silvia Maria Lavezzi Translational pharmacology benchmarking of a novel drug candidate for an autoimmune disease Wednesday 09:45-11:15

I-29 Olivier Le Tilly Non-linear pharmacokinetics of eculizumab in atypical haemolytic uremic syndrome Wednesday 09:45-11:15

I-30 Feiyan Liu A system pharmacology Boolean network model for the TLR4-mediated host response in early sepsis Wednesday 09:45-11:15

I-31 Igor Locatelli A Bayesian mixed treatment comparison meta-analysis of pulmonary arterial hypertension therapies Wednesday 09:45-11:15

I-32 Nicolas Luyckx Campsis: A generic, easy-to-use and intuitive PK/PD simulation platform based on R packages RxODE and mrgsolve Wednesday 09:45-11:15

I-33 Vincent Madelain Multicompartmental PKPD model to inform active exposure of nucleic acid therapeutic candidate in CNS disease Wednesday 09:45-11:15

I-34 Parsshava Mehta Application of interspecies PBPK modeling to characterize BBB permeability and assess target site exposure-response using levetiracetam as model drug Wednesday 09:45-11:15

I-35 Frano Mihaljevic Development of a level A in vitro/in vivo correlation (IVIVC) using applications of the MonolixSuite Wednesday 09:45-11:15

I-36 Anna Mishina Simulation of Rituximab and Natalizumab biomarker efficacy using simplified QSP model of B- and T- lymphocyte dynamics in Multiple Sclerosis Wednesday 09:45-11:15

I-37 Joo Young Na Population pharmacokinetic analysis of omeprazole according to CYP2C19 polymorphism in elderly subjects Wednesday 09:45-11:15

I-38 Chiara Nicolò MS TreatSim: A clinical trial simulator for Relapsing-remitting Multiple Sclerosis Wednesday 09:45-11:15

I-39 Marije Otto Application of Item Response Theory in Early Phase Clinical Trials: Utilization of a Reference Model to Analyse the Montgomery-Åsberg Depression Rating Scale. Wednesday 09:45-11:15

I-40 Theodoros Papathanasiou PKPD Exploratory Graphics (xGx) Cheat Sheet Wednesday 09:45-11:15

I-41 Tiffany Pela Quality of Life and Symptom Burden Among Patients With Eosinophilic Esophagitis in a Real-World Setting Wednesday 09:45-11:15

I-42 Carlos Perez-Ruixo Population pharmacokinetic modelling of selexipag and its active metabolite after oral and intravenous administration in adult pulmonary arterial hypertension patients Wednesday 09:45-11:15

I-43 Christoph Pfaffendorf Population pharmacokinetic model of atovaquone in infants to adults Wednesday 09:45-11:15

I-44 Thao Nguyen Pham Combining aggregate data and individual patient/subject data in model-based meta-analysis: An illustrative case study of tofacitinib in rheumatoid arthritis patients Wednesday 09:45-11:15

I-45 Elodie Plan Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357 treatment Wednesday 09:45-11:15

I-46 Anne Ravix Population pharmacokinetic study of lacosamide in children and adults with epilepsy Wednesday 09:45-11:15

I-47 Mar Ribera I Armengol A perspective on the kinetics of the oral administration of Mirabegron to treat overactive bladder in spinal cord injury patients Wednesday 09:45-11:15

I-48 Christelle Rodrigues Using preclinical data to predict human pharmacokinetics of monoclonal antibodies for first-in-human dose setting: A review of five internal case studies Wednesday 09:45-11:15

I-49 Karine Rodriguez-Fernandez External validation of a population pharmacokinetic model of adalimumab in patients with hidradenitis suppurativa Wednesday 09:45-11:15

I-50 Viktor Rognås An integrated semi-mechanistic model to predict the outcome of drug-target effects on the erythropoietic system Wednesday 09:45-11:15

I-51 Sergio Sánchez Herrero Ground-breaking software for modelling, simulation, optimization, estimation and validation applications in drug development timeline processes. Wednesday 09:45-11:15

I-52 Marina Savelieva Pharmacometrics and Integrated Evidence Generation: example of ligelizumab in Chronic Spontaneous Urticaria Wednesday 09:45-11:15

I-53 Daniel Seeler Towards a qualitative systems biology model to study the effect of blood flow responsive CCM and NO signaling on endothelial cell morphology Wednesday 09:45-11:15

I-54 Sejung Hwang Population pharmacokinetic analysis to investigate the effect of ethnicity for extrapolating data from Caucasians to Koreans in eslicarbazepine acetate therapy Wednesday 09:45-11:15

I-55 Alexander Solms Reduced FXI levels do not appear to increase bleeding risk in End-Stage Kidney Disease patients - results from an exploratory PK/PD and ER analysis of FXI-ASO Wednesday 09:45-11:15

I-56 Gilles Tiraboschi Population Pharmacokinetic and Pharmacodynamic Analyses of Olipudase alfa in Adult and Pediatric Patients with the rare Acid Sphingomyelinase Deficiency (Niemann-Pick) lysosomal storage disease Wednesday 09:45-11:15

I-57 Thi Quyen Tran Population pharmacokinetics of a truncated milk fat globule-EGF factor 8 (NP-011) for optimal dose prediction on liver fibrosis Wednesday 09:45-11:15

I-58 Pauline Traynard Validation of non-compartmental analysis (NCA) and bioequivalence results of PKanalix with respect to Phoenix WinNonLin and SAS. Wednesday 09:45-11:15

I-59 carla troisi Population pharmacokinetics of continuous infusion ampicillin in the treatment of enterococcal infections in adult hospitalised patients Wednesday 09:45-11:15

I-60 Monika Twarogowska A library of parent-metabolite models for the MonolixSuite Wednesday 09:45-11:15

I-61 Paul van den Berg Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis Wednesday 09:45-11:15

I-62 Marinda van de Kreeke Identifiability of drug effects in turn-over models with increasing complexity Wednesday 09:45-11:15

I-63 Xiaofeng Wang Exposure–response modelling of aripiprazole and brexpiprazole in adults and adolescents with schizophrenia to support extrapolation of efficacy in adolescents Wednesday 09:45-11:15

I-64 Zhigang Wang Higher clearance of therapeutic antibodies is associated with worse endoscopic outcomes in patients with Crohn’s disease Wednesday 09:45-11:15